PublishedJanuary 30, 2019 Category Publications A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
PublishedOctober 2, 2018 Category PARI News PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).
PublishedJune 6, 2018 Category PARI Publications Monitoring nebuliser usage & lung function in clinical trials.
PublishedDecember 12, 2017 Category PARI Publications Monitoring adherence to treatment regimen of inhaled medication use in a clinical trial with an investigational eFlow nebulizer (eTrack).
PublishedDecember 7, 2017 Category PARI News MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow Technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)
